Preventive treatment of tripdiolide ameliorates kidney injury in diabetic mice by modulating the Nrf2/NF-κB pathway

Bo Yuan1, Dan Jia1, Baoshan Gao1

  • 1Department of Urology, The First Hospital of Jilin University, Changchun, China.

PubMed
Abstract

Insights

Tripdiolide shows promise in preventing diabetic kidney injury by improving gut microbiota, reducing inflammation, and combating oxidative stress. This research offers new therapeutic strategies for diabetic nephropathy.

Area of Science:

  • Nephrology
  • Pharmacology
  • Microbiology

Background:

  • Diabetic kidney injury (DKI) is a major complication of diabetes.
  • Tripdiolide has shown protective effects in lupus nephritis, but its role in DKI is unclear.

Purpose of the Study:

  • To investigate the preventive effects of tripdiolide on diabetic kidney injury in a mouse model.
  • To explore the underlying mechanisms, including impacts on gut microbiota, oxidative stress, and inflammation.

Main Methods:

  • A diabetes mouse model was used for preventive tripdiolide treatment.
  • Evaluated diabetes-related factors, kidney pathology, gut microbiota composition, oxidative stress, and inflammation markers.
  • Assessed cytokine expression and protein pathway activation, including Nrf2 and NF-κB signaling.

Main Results:

  • Tripdiolide suppressed hyperglycemia and elevated hemoglobin, reduced creatinine and blood urea nitrogen, and mitigated kidney damage.
  • Alleviated inflammatory cell infiltration and regulated gut microbiota, notably affecting *Allobaculum*, *Dubosella*, and *Prevotella*.
  • Attenuated renal oxidative stress and inflammation via Nrf2 pathway activation and NF-κB/NLRP3 inhibition.

Conclusions:

  • Tripdiolide may protect against hyperglycemia-induced kidney injury by modulating gut microbiota, Nrf2/NF-κB pathway, oxidative stress, and inflammation.
  • Provides evidence for developing tripdiolide as a preventive therapy for diabetic nephropathy.